Relapse Mechanism and Treatment Strategy After Chimeric Antigen Receptor T-Cell Therapy in Treating B-Cell Hematological Malignancies

Overview

Journal Technol Cancer Res Treat

Specialties Biomedical Engineering
Oncology
Pharmacology

Date 2022 Aug 22

PMID 35989682

Authors

Danni Xie

Xin Jin

Rui Sun

Meng Zhang

Jiaxi Wang

Xia Xiong

Xiaomei Zhang

Mingfeng Zhao

Affiliations

Soon will be listed here.

Abstract

Over the past few decades, immunotherapy has revolutionized the modern medical oncology field. Chimeric antigen receptor (CAR)-T cell therapy has a promising curative effect in the treatment of hematological malignancies. Anti-CD19 CAR-T cells are the most mature CAR-T cells recently studied and in recent years it has achieved a complete remission rate of approximately 90% in the treatment of B-cell acute lymphoblastic leukemia (B-ALL). Although CAR-T cell therapy has greatly alleviated the disease in patients with leukemia or lymphoma, some of them still relapse after treatment. Therefore, in this article, we discuss the factors that may contribute to disease relapse following CAR-T cell therapy and summarize potential strategies to overcome these obstacles, thus providing the possibility of improving standard treatment regimens.

Citing Articles

Unveiling the potential of CLL-1: a promising target for AML therapy.

Soleimani Samarkhazan H, Zehtabcheh S, Seraji H, Beqaj S, Tayefeh S, Mohammadi M Biomark Res. 2025; 13(1):28.

PMID: 39940055 PMC: 11823018. DOI: 10.1186/s40364-025-00738-6.

Combination of CAR‑T cell therapy and radiotherapy: Opportunities and challenges in solid tumors (Review).

Zhong L, Li Y, Muluh T, Wang Y Oncol Lett. 2023; 26(1):281.

PMID: 37274466 PMC: 10236127. DOI: 10.3892/ol.2023.13867.

Bicistronic CAR-T cells targeting CD123 and CLL1 for AML to reduce the risk of antigen escape.

Xie D, Jin X, Sun R, Zhang M, Lu W, Cao X Transl Oncol. 2023; 34:101695.

PMID: 37224766 PMC: 10302120. DOI: 10.1016/j.tranon.2023.101695.

References

Golab K, Grose R, Placencia V, Wickrema A, Solomina J, Tibudan M . Cell banking for regulatory T cell-based therapy: strategies to overcome the impact of cryopreservation on the Treg viability and phenotype. Oncotarget. 2018; 9(11):9728-9740. PMC: 5839397. DOI: 10.18632/oncotarget.23887. View

Orlando E, Han X, Tribouley C, Wood P, Leary R, Riester M . Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat Med. 2018; 24(10):1504-1506. DOI: 10.1038/s41591-018-0146-z. View

Munshi N, Anderson Jr L, Shah N, Madduri D, Berdeja J, Lonial S . Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2021; 384(8):705-716. DOI: 10.1056/NEJMoa2024850. View

Wang J, Jensen M, Lin Y, Sui X, Chen E, Lindgren C . Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains. Hum Gene Ther. 2007; 18(8):712-25. DOI: 10.1089/hum.2007.028. View

Chen Y, Sun C, Landoni E, Metelitsa L, Dotti G, Savoldo B . Eradication of Neuroblastoma by T Cells Redirected with an Optimized GD2-Specific Chimeric Antigen Receptor and Interleukin-15. Clin Cancer Res. 2019; 25(9):2915-2924. DOI: 10.1158/1078-0432.CCR-18-1811. View

Wei J, Han X, Bo J, Han W . Target selection for CAR-T therapy. J Hematol Oncol. 2019; 12(1):62. PMC: 6587237. DOI: 10.1186/s13045-019-0758-x. View

Dai H, Wu Z, Jia H, Tong C, Guo Y, Ti D . Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. J Hematol Oncol. 2020; 13(1):30. PMC: 7126394. DOI: 10.1186/s13045-020-00856-8. View

Hamieh M, Dobrin A, Cabriolu A, van der Stegen S, Giavridis T, Mansilla-Soto J . CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature. 2019; 568(7750):112-116. PMC: 6707377. DOI: 10.1038/s41586-019-1054-1. View

Zheng S, Asnani M, Thomas-Tikhonenko A . Escape From ALL-CARTaz: Leukemia Immunoediting in the Age of Chimeric Antigen Receptors. Cancer J. 2019; 25(3):217-222. PMC: 6617517. DOI: 10.1097/PPO.0000000000000381. View

10.

Ruella M, Xu J, Barrett D, Fraietta J, Reich T, Ambrose D . Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat Med. 2018; 24(10):1499-1503. PMC: 6511988. DOI: 10.1038/s41591-018-0201-9. View

11.

Sotillo E, Barrett D, Black K, Bagashev A, Oldridge D, Wu G . Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. Cancer Discov. 2015; 5(12):1282-95. PMC: 4670800. DOI: 10.1158/2159-8290.CD-15-1020. View

12.

Maude S, Laetsch T, Buechner J, Rives S, Boyer M, Bittencourt H . Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):439-448. PMC: 5996391. DOI: 10.1056/NEJMoa1709866. View

13.

Zhang M, Jin X, Sun R, Xiong X, Wang J, Xie D . Optimization of metabolism to improve efficacy during CAR-T cell manufacturing. J Transl Med. 2021; 19(1):499. PMC: 8650271. DOI: 10.1186/s12967-021-03165-x. View

14.

Berdeja J, Madduri D, Usmani S, Jakubowiak A, Agha M, Cohen A . Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021; 398(10297):314-324. DOI: 10.1016/S0140-6736(21)00933-8. View

15.

Fischer J, Paret C, El Malki K, Alt F, Wingerter A, Neu M . CD19 Isoforms Enabling Resistance to CART-19 Immunotherapy Are Expressed in B-ALL Patients at Initial Diagnosis. J Immunother. 2017; 40(5):187-195. PMC: 5424577. DOI: 10.1097/CJI.0000000000000169. View

16.

Wei J, Luo C, Wang Y, Guo Y, Dai H, Tong C . PD-1 silencing impairs the anti-tumor function of chimeric antigen receptor modified T cells by inhibiting proliferation activity. J Immunother Cancer. 2019; 7(1):209. PMC: 6686487. DOI: 10.1186/s40425-019-0685-y. View

17.

June C, Maus M, Plesa G, Johnson L, Zhao Y, Levine B . Engineered T cells for cancer therapy. Cancer Immunol Immunother. 2014; 63(9):969-75. PMC: 4142345. DOI: 10.1007/s00262-014-1568-1. View

18.

Wei G, Zhang Y, Zhao H, Wang Y, Liu Y, Liang B . CD19/CD22 Dual-Targeted CAR T-cell Therapy for Relapsed/Refractory Aggressive B-cell Lymphoma: A Safety and Efficacy Study. Cancer Immunol Res. 2021; 9(9):1061-1070. DOI: 10.1158/2326-6066.CIR-20-0675. View

19.

Adeel K, Fergusson N, Shorr R, Atkins H, Hay K . Efficacy and safety of CD22 chimeric antigen receptor (CAR) T cell therapy in patients with B cell malignancies: a protocol for a systematic review and meta-analysis. Syst Rev. 2021; 10(1):35. PMC: 7819297. DOI: 10.1186/s13643-021-01588-7. View

20.

Ruella M, Barrett D, Kenderian S, Shestova O, Hofmann T, Perazzelli J . Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. J Clin Invest. 2016; 126(10):3814-3826. PMC: 5096828. DOI: 10.1172/JCI87366. View